Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
Luckily for you, we at StockStory have no conflicts of interest - our sole job is to help you find genuinely promising companies. Keeping that in mind, here is one stock where Wall Street’s excitement appears well-founded and two where analysts may be overlooking some important risks.
Two Stocks to Sell:
Transcat (TRNS)
Consensus Price Target: $101.33 (34.8% implied return)
Serving the pharmaceutical, industrial manufacturing, energy, and chemical process industries, Transcat (NASDAQ: TRNS) provides measurement instruments and supplies.
Why Does TRNS Worry Us?
- Costs have risen faster than its revenue over the last five years, causing its operating margin to decline by 2.8 percentage points
- Earnings per share fell by 6.8% annually over the last two years while its revenue grew, partly because it diluted shareholders
- Diminishing returns on capital from an already low starting point show that neither management’s prior nor current bets are going as planned
Transcat’s stock price of $75.16 implies a valuation ratio of 38.9x forward P/E. Check out our free in-depth research report to learn more about why TRNS doesn’t pass our bar.
Purple (PRPL)
Consensus Price Target: $0.83 (96% implied return)
Founded by two brothers, Purple (NASDAQ: PRPL) creates sleep and home comfort products such as mattresses, pillows, and bedding accessories.
Why Is PRPL Risky?
- Sales tumbled by 8.4% annually over the last five years, showing consumer trends are working against its favor
- Diminishing returns on capital from an already low starting point show that neither management’s prior nor current bets are going as planned
- Short cash runway increases the probability of a capital raise that dilutes existing shareholders
Purple is trading at $0.42 per share, or 0.1x forward price-to-sales. To fully understand why you should be careful with PRPL, check out our full research report (it’s free).
One Stock to Buy:
Skyward Specialty Insurance (SKWD)
Consensus Price Target: $60.45 (31.4% implied return)
Founded in 2006 to serve markets where standard insurance coverage falls short, Skyward Specialty Insurance (NASDAQ: SKWD) provides customized commercial property, casualty, and health insurance solutions for underserved or specialized market niches.
Why Are We Backing SKWD?
- Net premiums earned surged by 27.6% annually over the past two years, reflecting strong market share gains this cycle
- Market share will likely rise over the next 12 months as its expected revenue growth of 27.9% is robust
- Impressive 26% annual book value per share growth over the last two years indicates it’s building equity value this cycle
At $46 per share, Skyward Specialty Insurance trades at 1.5x forward P/B. Is now the time to initiate a position? Find out in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
